When Danazol Fails to Achieve Haemoglobin Response in Myelofibrosis-Related Anaemia with Adequate Serum Erythropoietin
This protocol applies to patients with primary myelofibrosis who have anaemia alongside an adequate serum erythropoietin level (≥500 mU/mL), and in whom a prior treatment attempt did not produce the expected haemoglobin improvement.
Escalation Trigger — Previous Line Did Not Succeed
The prior treatment involved a trial of danazol, with or without ruxolitinib, administered for a minimum of 12 weeks over a 6-month period. The goal of that line was a haemoglobin response — a meaningful rise in haemoglobin assessed at 6 months. Failure to achieve that response is the indication for moving to this next-line protocol.
Clinical Context
Myelofibrosis-related anaemia with an adequate serum erythropoietin level (≥500 mU/mL) defines a specific sub-population in which the treatment pathway diverges from patients with lower EPO levels — those below 500 mU/mL would typically merit an erythropoiesis-stimulating agent trial before this step.
Next-Line Approach — Partial Overview
Following danazol failure in this setting, several alternative options from different therapeutic classes may be considered, with the choice informed by local availability. The complete structured protocol — covering which agents apply, under what conditions, and in what order — is available via the link below.